NCT01817985View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Chronic Hepatitis C
Interventions
DRUG

GS-5816

Trial Locations (6)

32806

Investigational Site, Orlando

32809

Investigational Site, Orlando

33014

Investigational Site, Miami

33169

Investigational Site, Miami

78215

Investigational Site, San Antonio

00927

Investigational Site, San Juan

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT01817985 - A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment | Biotech Hunter | Biotech Hunter